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Background: Cytokines are the primary mediators of inflammation and also influence matrix metalloproteinase expres-
sion, both of which are important in development of abdominal aortic aneurysm (AAA). A significant, but as yet
unknown, familial factor contributes to the pathogenesis of AAA. Many cytokine genes contain polymorphic sites, some of
which affect cytokine production in vitro. Cytokine gene polymorphisms may therefore influence the pathogenesis of AAA.
The purpose of this study was to determine whether there is any association between cytokine gene polymorphisms and AAA.
Methods and Results: This case-control study comprised 100 patients with AAA and 100 age-matched and sex-matched
control subjects. For each case and control subject in the study, genotypes at the following cytokine gene polymorphic loci
were determined: interleukin (IL)–1 3953, IL-6 174, IL-10 1082, IL-10 592, and tumor necrosis factors-
308. Allele and genotype frequencies were compared between AAA and control groups, and odds ratios (OR) were
calculated for the presence of AAA with each allele at each locus examined as risk factors. The IL-10 1082 A allele was
significantly more common in the AAA group than the control group (P  .03). The OR for the IL-10 1082 A allele
as a risk factor for AAA was 1.8 (95% confidence interval, 0.9-3.6).
Discussion: These associations suggest a significant role for IL-10 in the pathogenesis of AAA. This association of AAA
with the IL-10 1082 A allele is also biologically plausible; the IL-10 1082 A allele is associated with low IL-10
secretion, and it may be that AAA develops in patients who are unable to mount the same anti-inflammatory response as
those who do not have AAA. (J Vasc Surg 2003;37:999-1005.)
The precise cause of abdominal aortic aneurysm (AAA)
is unknown. The principal structural proteins in arterial
walls are collagen and elastin. Aortic wall samples from
AAA show marked loss of elastin compared with normal
aortic wall,1 and this loss of mural elastin has been sug-
gested as the primary event in aneurysm formation.2 While
the total amount of collagen in AAA walls is usually pre-
served,3 there is increased collagen turnover in AAA.4 The
turnover of extracellular matrix proteins such as elastin and
collagen is regulated by matrix metalloproteinases
(MMPs), and elevated levels of MMPs have been detected
in AAA tissue compared with normal aortic wall tissue.5,6
An important source of MMPs in AAA tissue are tissue
macrophages,7 which form part of a chronic cellular inflam-
matory infiltrate that is a characteristic of AAA aortic
wall.8,9 The production of MMPs and tissue inhibitors of
metalloproteinases is in part regulated by cytokines,10,11
which also have a role in chronic inflammation.
Cytokines are the principal mediators of inflammation.
Tumor necrosis factor- (TNF-) and interleukin-1 (IL-
1) are proinflammatory cytokines produced by macro-
phages and other cells early in the inflammatory response.
They cause endothelial and neutrophil activation and stim-
ulate further cytokine release by inflammatory cells.12,13
IL-6 is another proinflammatory cytokine that is produced
by nucleated cells after stimulation by other cytokines.
IL-10 is a potent anti-inflammatory cytokine. It inhibits
macrophage function14 and acts indirectly on T lympho-
cytes by interfering with the antigen presenting cell signals
to the T cells.15 It reduces proinflammatory cytokine pro-
duction by macrophages, neutrophils, and T cells.
Many cytokine genes contain polymorphic sites, and
although more than 900 such polymorphisms have been
identified, only a small minority of these polymorphisms
affect cytokine transcription in vitro.16 For example, the
IL-10 gene contains three polymorphic sites, at the1082,
819, and592 positions in relation to the start codon.17
The bases present at these three sites are either guanine or
adenine (1082), cytosine or thymine (819), and cyto-
sine or adenine (592). The polymorphisms at 819 and
592 are linked, only 819/592 cytosine-cytosine
(CC) or thymine-adenine (TA) haplotypes existing. The
presence of an adenine base at1082 results in an approx-
imately 25% reduction in IL-10 production by maximally
stimulated peripheral blood lymphocytes,18 and the
1082/819/592 guanine-cytosine-cytosine haplo-
type is also associated in vitro with higher IL-10 production
than any other haplotype.18 For the IL-6 174 single
nucleotide polymorphism, where there is either a guanine
(G) or cytosine (C) base at this site, the G allele results in
plasma IL-6 levels two to three times higher in healthy
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subjects.19 At the TNF- 308 polymorphic site the pres-
ence of an adenine (A) base, substituted for the more
common guanine base, is associated with TNF- gene
transcription six to nine times higher in human B cells
virally transfected with this polymorphism,20 and a thymine
(T) base at the IL-1 3953 polymorphic site (more
commonly cytosine) is associated with higher IL-1 pro-
duction by isolated peripheral blood monocytes in response
to lipopolysaccharide stimulation.21
AAA have a significant genetic component in their
cause; 11% to 20% of patients with AAA have a family
history of AAA.22,23 The screen-detected prevalence of AAA
in siblings of patients with AAA has been estimated at 15% to
36%, compared with the population prevalence of between 2%
and 8%.24,25 Given the role of cytokines in mediating inflam-
mation and MMP production, it is feasible that cytokine gene
polymorphisms may be responsible for this genetic compo-
nent in the pathogenesis of AAA. The purpose of this study
was to determine whether there is any association between
AAA and the following cytokine gene polymorphisms:
TNF- 308, IL-1 3953, IL-6 174, IL-10 1082,
IL-10592, and IL-101082/819/592 haplotype.
METHODS
Selection of cases and control subjects. Cases con-
sisted of 100 consecutive patients who consented to take
part in the study, who were admitted to either the Leicester
Royal Infirmary or the Leicester General Hospital for open
AAA repair. Patients admitted for elective surgery and
those admitted for either emergency repair of symptomatic
nonruptured AAA or emergency repair of ruptured AAA
were included. All patients were white Europeans. All pa-
tients who underwent elective surgery had AAA greater
than 5.5 cm in diameter. Sex-matched and age-matched
(5 years) white control subjects were recruited from
patients attending vascular outpatient clinics and those
admitted for surgery at the Leicester General Hospital. In
control subjects, when aortic diameter had not been as-
sessed either radiologically or at surgery, clinical examina-
tion was used to exclude those with incidental AAA. The
presence or absence of the following cardiovascular risk
factors were recorded for both patients and control subjects
unless these could not be accurately determined (eg, un-
conscious patient undergoing surgery to repair ruptured
AAA who subsequently did not survive without regaining
consciousness): smoking history, current smoker, hyperlip-
idemia, previous cerebrovascular accident, angina, hyper-
tension, previous myocardial infarction, and diabetes mel-
litus. Patients were defined as having hyperlipidemia or
hypertension if they were receiving pharmacologic treat-
ment for these conditions at recruitment into the study.
The study was approved by the Leicestershire regional
ethics committee, and all patients, or in the case of uncon-
scious patients their relatives, gave informed consent to
participate in the study.
Cytokine polymorphism genotyping. Peripheral
blood was drawn from each patient (at induction of anaes-
thesia) or control subject into sterile collection tubes con-
taining ethylenediaminetetraacetic acid (EDTA) as an an-
ticoagulant and centrifuged at 770g for 10 minutes. The
buffy coat was drawn off, and DNA was extracted with
proteinase K digestion (Sigma, Poole, UK) with subse-
quent salt extraction and ethanol precipitation.26 DNA was
quantified with a fluorometer (Dynaquant 200; Hoefer
Pharmacia Biotech, San Francisco, Calif).
Genotypes were determined for the following loci by
induced heteroduplex genotyping: IL-1 3953, IL-6
174, IL-101082, IL-10592 and TNF-308. This
method has been validated in our laboratory with both the
polymerase chain reaction (PCR) restriction fragment
length polymorphism (RFLP) test (IL-1 3953, IL-6
174) and the PCR–single stranded polypeptide (SSP) test
(IL-10 1082, IL-10 592 and TNF- 308), and re-
sults were consistent with these more traditional methods.
Primers and heteroduplex generators (Oswel DNA,
Southampton, England) used were as described by Morse
et al.27 PCR mixes (25L) contained 2.5L of either DNA
(100 ng/L) or heteroduplex generator (0.5 ng/L), 200
mol of each deoxynucleotide triphosphate (Helena Bio-
sciences, Sunderland, UK), 0.5 mol of each forward and
reverse primer, 0.25 units of Taq polymerase (Helena Bio-
sciences), 1 Taq polymerase buffer (Helena Biosciences),
and magnesium chloride, as follows: TNF- 308 and
IL-10 1082, 2.5 mmol; IL-10 592, 2.0 mmol/L;
IL-13953 and IL-6174, 1.5 mmol. PCR parameters,
optimized for a Helena Biosciences Phoenix thermal cycler
were initial denaturation at 95° C for 5 minutes for all loci,
followed by 30 cycles (25 for TNF- 308) of denatur-
ation at 95° C for 1 minute; annealing at 59° C (TNF-
308), 60° C (IL-1 3953 and IL-6 174), 57° C
(IL-101082), or 62° C (IL-10592) for 1 minute; and
extension at 72° C for 1 minute, with a final extension at
72° C for 5 minutes.
After the initial PCR step, equal volumes (10 L) of
genomic DNA and heteroduplex generator amplicons were
mixed, heated to 95° C for 5 minutes, then allowed to cool
to 45° C over 25 minutes to allow DNA heteroduplex
formation. Heteroduplexes were stained with SYBR I green
(BioWhittaker Molecular Applications, Rockland, Me) and
Table I. Frequency of risk factors in case and control
groups for subjects for whom data were recorded
AAA
(n  91) %
Control
(n  100) % P*
Smoking history 84 92 73 73 	.001
Current smoker 24 26 23 23 .62
Hyperlipidaemia 20 22 14 14 .19
Previous CVA 2 2 6 6 .28
Angina 16 18 16 16 .85
Hypertension 55 60 36 36 	.001
Previous MI 20 22 12 12 .08
Diabetes mellitus 6 7 15 15 .07
AAA, abdominal aortic aneurysm; CVA, cerebrovascular accident; MI,
myocardial infarction.
*Fisher’s exact test.
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resolved on 15% Tris-Borate EDTA polyacrylamide minigels
(27.5:1 acrylamide:bis; Bio-Rad, Hemel Hempstead, UK)
run for 3 hours at a constant 100 V. Gels were visualised
with a dark reader.
Statistical analysis. The assumption of Hardy-Wein-
berg equilibrium was tested by comparing observed genotype
frequency in patients and control subjects with their expected
frequency at equilibrium based on the observed allele preva-
lences. Comparison was based on the 
2 test. Comparisons
between patient and control group risk factor, allele, geno-
type, and haplotype frequency were made with Fisher exact or

2 tests as appropriate. Mantel-Haenszel matched analysis of
patients and control subjects was performed with the presence
of each allele at each locus as “exposures.”
RESULTS
Demographics. All patients and control subjecs were
matched precisely for sex; 80 subjects in each group were
men (80%). Median age of the control group was 73 years
(range, 48-87 years), compared with 72 years (range,
48-85 years) in the patient group (P .49, Mann-Whitney
U test). Mean difference in age between patients and
control subjects was 0.6 years (range, 4 to 5 years).
Complete risk factor data were available for 91 patients
(91%) and all control subjects. The frequency of risk factors
in each groups is shown in Table I.
Allele and genotype frequency. Allele frequency and
observed and expected genotype frequency, the latter cal-
culated assuming Hardy-Weinberg equilibrium, are shown
in Table II (control group) and Table III (AAA group).
Observed genotypic distributions in both patients and con-
trol subjects were consistent with the assumption of Hardy-
Weinberg equilibrium. The IL-10 1082 A allele was
significantly more common in the AAA group compared
with the control group (P  .03, Fisher exact test) (Table
IV). The AAA group also had a lower frequency of the
IL-10 GCC haplotype (0.415) compared with the control
group (0.53), but this did not reach statistical significance
(P .07, 
2 5.32, 2 degrees of freedom [df]). There was
no significant difference in allele frequency between the
AAA and control groups for TNF- 308, IL-1 3953,
IL-6 174, or IL-10 592 loci (Table IV).
IL-1 3953 genotype frequency was significantly
different between the control and AAA groups (P  .04,

2  6.67, 2 df), with the TT genotype more common in
the control group than in the AAA group. IL-10 1082
AA genotype was more common in the AAA group than in
the control group, but not significantly so (P  .07, 
2 
5.264, 2 df). There was little difference in genotype fre-
quency for the other loci studied (Table V). IL-101082/
819/592 haplotypes were assumed from the allele fre-
quency identified at the 1082 and 592 positions (819
Table II. Control group: Allele frequency, observed and expected genotype frequency,* and comparison between
observed and expected genotype frequency
Locus Allele n
Allele
frequency
(%) Genotype
Observed
frequency
(%)
Expected
frequency
(%)

2
(2 df) P
TNF 308 G 158 79 GG 63 62
0.02 .99GA 32 33
A 42 21 AA 5 5
IL-1 3953 C 144 72 CC 55 52
1.04 .59CT 34 40
T 56 28 TT 11 8
IL-6 174 G 113 56.5 GG 28 32
1.34 .51GC 57 49
C 87 43.5 CC 15 19
IL-10 1082 G 106 53 GG 29 28
0.08 .96GA 48 50
A 94 47 AA 23 22
IL-10 592 C 157 78.5 CC 62 62
0.13 .94CA 33 34
A 43 21.5 AA 5 4
IL-10 haplotype GCC 106 53 GCC/GCC 29 28
ACC 51 25.5 GCC/ACC 25 27
ATA 43 21.5 GCC/ATA 23 23 0.43† .99
ACC/ACC 8 6
ACC/ATA 10 11
ATA/ATA 5 5
TNF, tumor necrosis factor; IL, interleukin; G, guanine; A, adenine; C, cytosine; T, thymine; df, degrees of freedom.
*Calculated with Hardy-Weinberg equation.
†5 df.
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and 592 alleles are linked). There was no difference in the
combinations of IL-10 haplotypes between the AAA group
and the control group (Table VI); however, the GCC/GCC
genotype, associated with higher IL-10 secretion than any
other combination of haplotypes, was more than one and a
half times as common in the control group than in the AAA
group (29% vs 17%, respectively; P .06, Fisher exact test).
Matched case-control analysis. The OR and 95%
confidence intervals (CI), evaluating the presence of each
allele studied as a risk factor for being a case, are shown in
Table III. AAA group: Allele frequency, observed and expected genotype frequency,* and comparison between
observed and expected genotype frequency
Locus Allele n
Allele
frequency
(%) Genotype
Observed
frequency
(%)
Expected
frequency
(%)

2
(2 df) P
TNF 308 G 158 79 GG 64 62
0.27 .8GA 30 33
A 42 21 AA 6 5
IL-1 3953 C 158 79 CC 60 62
1.67 .4CT 38 33
T 42 21 TT 2 5
IL-6 174 G 114 57 GG 33 32
0.02 .9GC 48 49
C 86 43 CC 19 19
IL-10 1082 G 83 41.5 GG 17 17
0.00 1.0GA 49 49
A 117 58.5 AA 34 34
IL-10 592 C 146 73 CC 55 53
0.50 0.7CA 36 40
A 54 27 AA 9 7
IL-10 haplotype GCC 83 41.5 GCC/GCC 17 17
ACC 63 31.5 GCC/ACC 26 26
ATA 54 27 GCC/ATA 23 23 0.97† .9
ACC/ACC 12 10
ACC/ATA 13 17
ATA/ATA 9 7
TNF, Tumor necrosis factor; IL, interleukin; G, guanine; A, adenine; C, cytosine; T, thymine; df, degrees of freedom.
*Calculated with Hardy-Weinberg equation.
†5 df.
Table IV. Comparison of allele frequency in control and case groups
Locus Allele
Control AAA
P*n
Frequency
(%) n
Frequency
(%)
TNF 308 G 158 79 158 79 1.00A 42 21 42 21
IL-1 3953 C 144 72 158 79 .13T 56 28 42 21
IL-6 174 G 113 56.5 114 57 .92C 87 43.5 86 43
IL-10 1082 G 106 53 83 41.5 .03A 94 47 117 58.5
IL-10 592 C 157 78.5 146 73 .24A 43 21.5 54 27
TNF, Tumor necrosis factor; IL, interleukin; G, guanine; A, adenine; C, cytosine; T, thymine.
*Fisher exact test.
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the Figure. OR was obtained with matched-pair analysis of
each case with its matched control. Alleles at three loci had
OR greater than 1: IL-1 3953 C (OR, 5.50; 95% CI,
1.20-51.07); IL-10 1082 A (OR, 1.80; 95% CI, 0.92-
3.64); IL-10 592 C (OR, 1.67; 95% CI, 0.55-5.58).
While the IL-1 3953 C allele was the only one of these
95% CIs to exclude 1, only 2 patients and 11 controls were
not “exposed” to this risk factor.
DISCUSSION
Our data demonstrate that in patients with AAA the
IL-101082 A allele is significantly more common than in
age-matched and sex-matched control subjects. IL-10 A
allele frequency in the control group was also similar to that
observed by other authors in other groups of white per-
sons,18,28 meaning that this is not likely to be due to
chance. The IL-10 1082/819/592 GCC/GCC ge-
notype was more common in the control group than in the
AAA group. The distribution of IL-1 3953 genotypes
was significantly different in patients with AAA compared
with the control group. The OR for having AAA was 5.5 in
those with an IL-1 3953 C allele, with a 95% CI that
excluded a value of 1, and 1.8 in those with an IL-10
1082 A allele.
Table V. Case and control genotype frequency for five loci studied
Locus Genotype
Control
(n)
AAA
(n) 
2 (2 df) P
TNF 308 GG 63 64
0.16 .92GA 32 30
AA 5 6
IL-1 3953 CC 55 60
6.67 .04CT 34 38
TT 11 2
IL-6 174 GG 28 33
1.65 .44GC 57 48
CC 15 19
IL-10 1082 GG 29 17
5.26 .07GA 48 49
AA 23 34
IL-10 592 CC 62 55
1.69 .43CA 33 36
AA 5 9
TNF, tumor necrosis factor; IL, interleukin; G, guanine; A, adenine; C, cytosine; T, thymine.
Matched analysis odds ratios and their 95% confidence intervals for each genetic locus as a risk for AAA. *IL-13953
C confidence interval truncated; true value, 1.20-51.07. TNF, Tumor necrosis factor; IL, interleukin; G, guanine; A,
adenine; C, cytosine; T, thymine.
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We do not suggest that either of these polymorphisms
should be viewed as a consistent genetic marker for AAA,
because many patients with AAA in this study did not
possess the alleles associated with AAA. Rather, this study
strongly suggests a prime etiologic role for cytokines in the
pathogenesis of AAA. The IL-10 1082 A allele, which
was more common in the AAA group, is associated with
decreased IL-10 production in in vitro studies, and the
IL-101082/819/592 GCC/GCC genotype, which
was more common in the control group, is associated with
high IL-10 production.18 Since IL-10 is predominantly an
anti-inflammatory cytokine, it may be that patients who
produce less IL-10 cannot limit the inflammatory response
to any particular stimulus and thus the inflammatory cas-
cades may persist longer in these patients, predisposing
them to AAA formation. Also, IL-10 may be acting directly
to limit the action of MMPs. In animal and laboratory
studies IL-10 inhibited production of MMPs.28-30
The findings regarding the IL-1 3953 polymor-
phism must be examined with caution because of the small
number of patients in both the AAA and control groups who
had either a T allele or a TT genotype. The IL-1 allele
frequency observed in both the control and AAA groups is
similar to that in other studies, and the genotype frequency in
the control group is similar to that observed in other groups of
healthy white persons. However, the genotype frequency in
the AAA group is different from that noted in these studies,31
which suggests that this difference may be true. The finding
that the IL-1 C allele was associated with AAA was surpris-
ing. IL-1 is a proinflammatory cytokine, and the C allele is
associated with low IL-1 production in in vitro studies.22 It
would therefore be expected that high secretor status for
IL-1would predispose to AAA formation. However, clinical
findings contrary to those demonstrated in basic laboratory
studies have been found,32 and it has been suggested that this
effect may be due to either different cells (which may exhibit
different responses between genotypes from those studied in
vitro) being responsible for in vivo cytokine production or
different responses to physiologic stimulation rather than that
to single supramaximal artificial stimuli as used in in vitro
experiments. It is not clear whether our findings are the result
of this type of phenomenon or due to statistical chance.
The cytokine genes examined were chosen in part
because they all affect cytokine secretion in vitro, but also
because these four genes are located on separate autosomes
and the confounding effect of genetic linkage between
these genes is not present (TNF-, chromosome 6; IL-1,
chromosome 2; IL-6, chromosome 7; IL-10, chromosome
1). However, the two IL-10 loci examined are clearly
closely linked, with only three haplotypes found in white
persons. The1082 A allele can be inherited with either an
A or C allele at592, which occurs evenly, and the1082
G allele is only inherited with a C allele at592. The IL-10
1082 polymorphism affects cytokine secretion indepen-
dently of the alleles present at the 819/592 positions.
The 592 locus only affects cytokine secretion as part of
the IL-10 haplotype, with the GCC/GCC genotype show-
ing higher secretion than any other combination of haplo-
types. However, since the A allele was more common in the
AAA group and the GCC/GCC genotype more common
in the control group, this supports rather than conflicts
with the theory that reduced IL-10 production has a role in
AAA formation.
The limitations of this study lie principally in the con-
trol group. The method used to recruit controls in a
case-control study is a critical part of the study design.33 A
possible control group for this study would have been
patients undergoing the same diagnostic process as was
used to identify the cases but who were subsequently found
not to have AAA. This was explored during the design of
this study but found to be logistically impossible in the time
frame allotted for the study. The control group was re-
cruited from hospital areas where the cases had originated
from, ie, vascular outpatient departments and surgical wards,
to get the closest possible match with the cases. While this
method of control selection contributes to selection bias,34
that allele and genotype frequency in the control group was
similar to that found in other studies of white Europeans28
suggests that this bias is minimal in this study.
A further limitation in the control group was that their
aortic diameter was not formally measured. Many, however,
had undergone laparotomy, or preoperative or outpatient
ultrasound or computed tomography, and all had been exam-
ined clinically for the presence of AAA. It is still possible that
Table VI. IL-10 1082/819/592 haplotype and genotype frequency for control and case groups
Control AAA

2 df Pn Frequency (%) n Frequency (%)
IL-10 haplotype GCC 106 53 83 41.5
5.31 2 .07ACC 51 25.5 63 31.5
ATA 43 21.5 54 27
IL-10 genotype GCC/GCC 29 29 17 17
GCC/ACC 25 25 26 26
GCC/ATA 23 23 23 23 5.48 5 .36
ACC/ACC 8 8 12 12
ACC/ATA 10 10 13 13
ATA/ATA 5 5 9 9
IL, Interleukin; G, guanine; C, cytosine; A, adenine; T, thymine; df, degrees of freedom.
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some control subjects had occult AAA. This is unlikely to have
affected the findings of this study. The prevalence of AAA in
the case group was 100% and in the control group was likely to
be less than the prevalence in the general population (3%-
8%25,26). Thus the confounding effect of the presence of a few
AAA in the control group is likely similarly small. However,
this also means that the differences in allele frequency may
actually be an underestimate of the true population difference
between those with AAA and those without, with those con-
trol subjects with occult AAA contributing to the allele fre-
quency in the control group.
With the relatively small number of patients in this
study, we were unable to examine the role of epistasis, and
larger studies may be able to examine the interactions
between these and other genetic loci. Further research should
first be directed to confirm these findings in an independent
study, preferably with a more robust control group. If the
association between the IL-101082 A allele is confirmed, a
prospective cohort study would be required to prove a causal
relationship between AAA and this genetic locus. The insights
that this study gives for the role of cytokines in the pathogen-
esis of AAA may not merely be furthering understanding of
this complex process but may also suggest a possible therapeu-
tic option for small AAA. IL-10 therapy has been successful in
some chronic inflammatory diseases, with a good side-effect
profile,35 and IL-10 could therefore potentially be used to
treat small AAA.
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